Inter Partes Review in ANDA Litigation
2016
ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition
The Leahy-Smith America Invents Act (AIA) aimed to provide cost-effective alternatives to district court litigation through expedited review of issued patents in the United States Patent and Trademark Office (USPTO) through post-grant review. One procedure in particular, inter partes review (IPR), permits a petitioner to challenge an issued patent's validity under 35 U.S.C. §§ 102 and 103 based on patents and printed publications. The unique statutory framework of Hatch-Waxman litigation, however, requires patent owners and challengers alike to carefully consider the potential implications IPR has on current or anticipated Abbreviated New Drug Application (ANDA) litigation. Mark J. Feldstein, Ph.D. discusses the statute and regulations governing IPR, explain the unique interplay between the Hatch-Waxman Act and IPR proceedings, and provide helpful strategies for patent owners and challengers contemplating or anticipating concurrent ANDA litigation and post-grant review.
Related Professionals
Originally printed in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition in 2016. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.